February 7, 2018

Cerenion funded for cutting-edge brain monitoring

Cerenion's C-Trend technology reveals valuable information on the state of the brain at the bed-side, without requiring any changes to the care of the patient.
Cerenion's C-Trend technology reveals valuable information on the state of the brain at the bed-side, without requiring any changes to the care of the patient.
Cerenion

Finnish Cerenion has raised 500 000 euros in seed funding for its groundbreaking brain monitoring technology, that holds great potential for improving intensive care treatment.

Cerenion closed the seed investment round of 500 000 euros after securing a capital boost from Butterfly Ventures and Icebreaker.vc.

The funding will allow Cerenion to commercialise its C-Trend brain monitoring technology, which provides the world’s first practical method for measuring the brain function of intensive care patients.

“We are grateful for the trust shown in us by the investors today,” says doctor Timo Koskela, CEO and co-founder of Cerenion. “This investment enables us to bring C-Trend to market quickly and with a view of improving intensive care for patients worldwide.”

The C-Trend technology was developed at the University of Oulu and underwent clinical studies at Oulu University Hospital, as part of a Tekes-funded project. It is based on standard EEG-measurement, advanced machine learning algorithms and artificial intelligence.

Key personnel from the original research project set up Cerenion in May 2017 to commercialise the technology. To date, the development of the technology and business has been funded by more than 1.1 million euros.

Share: